(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 14.61% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.88%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.88%.
Ani Pharmaceuticals's revenue in 2026 is $923,706,000.On average, 10 Wall Street analysts forecast ANIP's revenue for 2026 to be $25,952,594,962, with the lowest ANIP revenue forecast at $24,565,120,560, and the highest ANIP revenue forecast at $27,112,614,544. On average, 10 Wall Street analysts forecast ANIP's revenue for 2027 to be $28,818,525,694, with the lowest ANIP revenue forecast at $26,043,576,890, and the highest ANIP revenue forecast at $32,526,039,260.
In 2028, ANIP is forecast to generate $31,616,219,980 in revenue, with the lowest revenue forecast at $26,680,450,386 and the highest revenue forecast at $35,187,260,654.